N/A
N=16
The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing
Chronic Obstructive Pulmonary Disease
Bottom Line
View on ClinicalTrials.gov: NCT01580423 ↗Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Jul 2013
Primary outcome: Primary: Intensity of Breathlessness — 80.8; 77.9 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- aprepitant (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Dartmouth-Hitchcock Medical Center
- Primary completion
- Mar 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intensity of Breathlessness |
80.8; 77.9 | — |
| PRIMARY Unpleasantness of Breathlessness |
76.2; 72.2 | — |
| SECONDARY Intensity of Pain |
85.8; 81.9 | — |
Summary
Substance P is released from sensory nerves and transmits pain information into the central nervous system. As pain and dyspnea share many characteristics, including similar neurological pathways, it is possible that substance P may contribute to the sensation of dyspnea. The hypothesis of the study is that patients with chronic obstructive pulmonary disease (COPD) will provide lower ratings of breathlessness during resistive load breathing with oral aprepitant, a medication that blocks the activity of substance P, compared with placebo.
Eligibility Criteria
Inclusion Criteria
- 50 years of age or older
- diagnosis of COPD
- former smoker > 10 pack-years
- clinical diagnosis of chronic bronchitis
- post-bronchodilator forced expiratory volume in one second (FEV1) 30 - 80% predicted
- FEV1/forced vital capacity ratio less than or equal to 70%
Exclusion Criteria
- current smoker
- pregnant women
- concomitant disease that might interfere with study procedures
- peripheral vascular disease or cold hypersensitivity
- drugs that might interfere with aprepitant
Data sourced from ClinicalTrials.gov (NCT01580423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.